Efficacy and safety of MEK inhibitors for NF1-associated symptomatic, inoperable plexiform neurofibromas: A systematic review and meta-analysis. (PubMed, PLoS One) - Oct 7, 2026 - "Eleven reports of nine studies (528 participants) met eligibility, covering selumetinib, mirdametinib, trametinib and binimetinib. Benefit is partial and depends on continued treatment. Optimal duration, comparative effectiveness and any effect on malignant transformation remain undefined."
Clinical • Journal • Retrospective data • Review • Genetic Disorders • Neurofibromatosis • Oncology • Pain • Solid Tumor • MAP2K1 • NF1
|
|
James Tonsgard; Sudarshawn Damodharan
|